GI Dynamics touts results of U.K. study

GI Dynamics (ASX:GID) said a retrospective study of its EndoBarrier device for patients with type 2 diabetes and obesity shows a significant reduction in HbA1c, weight, liver fat and cardiovascular disease (CVD) risks as well as a reduction in the need for insulin in some patients. The EndoBarrier device is a plastic gut sleeve designed to prevent the absorption of nutrients from food as it exits the stomach and enters the intestinal tract, according to the Lexington, Mass.-based company. Get the full story on our sister site, Medical Design & Outsourcing. The post GI Dynamics touts results of U.K. study appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Blog Business/Financial News Clinical Trials Diabetes Featured News Well Research & Development Surgical Source Type: news